Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Astria Therapeutics, Inc. (ATXS : NSDQ)
 
 • Company Description   
Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON.

Number of Employees: 29

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.38 Daily Weekly Monthly
20 Day Moving Average: 12,316 shares
Shares Outstanding: 13.02 (millions)
Market Capitalization: $44.00 (millions)
Beta: 1.38
52 Week High: $15.72
52 Week Low: $3.36
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -44.22% -37.19%
12 Week -50.51% -45.60%
Year To Date -37.29% -13.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 High Street Floor 28
-
Boston,MA 02110
USA
ph: 617-349-1971
fax: 617-273-2637
investors@astriatx.com http://www.astriatx.com
 
 • General Corporate Information   
Officers
Jill C. Milne - President and Chief Executive Officer and Director
Kenneth Bate - Chairman
Noah Clauser - Chief Financial Officer and Treasurer
Michael Kishbauch - Director
Hugh Cole - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04635X102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 13.02
Most Recent Split Date: 8.00 (0.17:1)
Beta: 1.38
Market Capitalization: $44.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.31
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 18.04%
vs. Previous Quarter: -61.64%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -145.56
12/31/21 - -
09/30/21 - -1,116.02
ROA
03/31/22 - -31.00
12/31/21 - -21.95
09/30/21 - -25.25
Current Ratio
03/31/22 - 23.00
12/31/21 - 24.42
09/30/21 - 28.62
Quick Ratio
03/31/22 - 23.00
12/31/21 - 24.42
09/30/21 - 28.62
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.02
12/31/21 - 1.99
09/30/21 - 2.62
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 87.89
12/31/21 - 78.81
09/30/21 - 73.91
 

Powered by Zacks Investment Research ©